Medical devices, healthcare technology and the business of care
510(k) clearance · K261379

BD Veritor System for SARS-CoV-2

BD Diagnostic Solutions / Becton, Dickinson & Company · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONK261379

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for BD Veritor System for SARS-CoV-2, 510(k) number K261379, on 2026-10-27. The applicant is BD Diagnostic Solutions / Becton, Dickinson & Company of Sparks, MD. The submission was received 04/27/2026, falls under product code QVF and the Microbiology review panel, and was not reviewed by a third party.

SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The public record lists the classification name as a simple point-of-care device to directly detect SARS-CoV-2 viral targets from clinical specimens in near-patient settings. The page does not state which components or changes were assessed, the predicate device, or any performance data, so the scope of this clearance remains unknown from the cited record.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 27, 2026
FDA decision documents: 510(k) Premarket Notification

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261379
Regulatory pathway
510(k) premarket notification
Product code
QVF
Decision code
SESE
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings.

Product code
QVF
FDA device class
2

FDA decision timeline

  1. K261379 received

    Application receipt date recorded by FDA.

  2. K261379 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QVF

Product / regulatory recordCompanyPathwayDecision dateSource
Ortho Clinical Diagnostics Inc. (QuidelOrtho)510(k) clearanceSep 4, 2026FDA
CorDx, Inc.510(k) clearanceJun 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

BD Diagnostic Solutions / Becton, Dickinson & Company

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Sparks, MD

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records